7 results
To determine the beneficial effect of a single dose of 150 µg clonidine as an adjuvant to chirocaine in retrobulbar block.
(1) To establish the pharmacokinetic profile of clonidine following oral administration in children with suspected GH deficiency. (2) To relate the pharmacokinetics of clonidine to the observed expected (GH-response, cortisol response, depth and…
Primary:To assess the non-inferiority of the sedative properties of continuous intravenous (i.v.) clonidine compared to continuous i.v. midazolam in mechanically ventilated children and adolescents (0 - <18 years) admitted to a paediatric…
Primary objective:Plasma levels of clonidine, in order to describe pharmacokinetic and pharmacodynamic properties of intravenous clonidine in critically ill ventilated ICU patients.Secondary objectives are: * to evaluate the effect of a 3-hr loading…
Primary:To evaluate the efficacy of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 participants with NY-ESO-1- and/or LAGE-1a positive solid tumors.Secondary:To…
Primary:• To monitor participants for delayed AEs associated with administration of autologous cells that have been genetically modified by lentiviral vectorsSecondary:• To monitor Replication Competent Lentivirus (RCL).• To measure persistence of…
Primary:• To evaluate the safety and tolerability of autologous genetically modified T-cells (GSK3377794) in human leukocyte antigen (HLA) HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with NY-ESO-1 and/or LAGE-1a positive…